Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Patent
1997-06-13
1998-12-01
Saunders, David
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
4353201, 435 697, 4351723, 536 234, 536 2372, C12P 2100, C12N 1539, C12N 510, C07H 2104
Patent
active
058437789
ABSTRACT:
Disclosed are chimeric proteins that are useful for inhibiting complement. The chimeric protein termed VCPFc is a fusion protein in which (i) an immunoglobulin Fc region is fused to (ii) a polypeptide that comprises a portion of a vaccinia virus complement control protein which binds complement components C4b and C3b, but not iC3b rosettes. This protein can be use in xenograft transplantation methods (e.g., by treating the donor mammal or organ) and in methods for treating complement-mediated disorders (e.g., inflammation) generally. In a second chimeric protein, a transmembrane anchoring domain is fused to a polypeptide that comprises a portion of a vaccinia virus complement control protein which binds complement components C4b and C3b, but not iC3b rosettes. The transmembrane anchoring domain can be, for example, short consensus regions 3 through 15 of human complement receptor 2 protein. Expression of the transmembrane-anchored fusion protein in a transgenic animal provides a well-suited organ donor for xenograft transplantation.
REFERENCES:
patent: 5455165 (1995-10-01), Capon et al.
patent: 5643770 (1997-07-01), Mason et al.
Miller et al. Virology. 229:126-133, Mar. 3, 1997.
McKenzie et al. "Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein", The Journal of Infectious Diseases, 1992, vol. 166, pp. 1245-1250.
Kroshus et al., "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Xenotransplantation," Transplantation, Dec. 15, 1995, vol. 60, pp. 1194-1202.
Heckl-Ostreicher et al., "Functional Activity of the Membrane-Associated Complement Inhibitor CD59 in a Pig-To-Human in vitro Model for Hyperacute Xenograft Rejection", Clin. Exp. Immunol., 1995, vol. 102, pp. 589-595.
White et al, "Production of Pigs Transgenic for Human DAF to Overcome Complement-Mediated Hyperacute Xenograft Rejection in Man," Res. Immunol., Feb. 1996, vol. 147, No. 2, pp. 88-94.
Ahearn, Jr. Joseph M.
Baldwin, III William M.
Rosengard Ariella M.
Sanfilippo Alfred P.
Saunders David
The Johns Hopkins University School of Medicine
VanderVegt F. Pierre
LandOfFree
Use of chimeric vaccinia virus complement control proteins to in does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of chimeric vaccinia virus complement control proteins to in, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of chimeric vaccinia virus complement control proteins to in will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2395158